NCT04437017View on ClinicalTrials.gov

Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV

PHASE3CompletedINTERVENTIONAL

Enrollment

557

Participants

Timeline

Start Date

February 3, 2020

Primary Completion Date

May 1, 2022

Study Completion Date

July 1, 2022

Conditions

Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG

Olanzapine+NK-1 RA+5-HT3 RA

On day 1-4, Olanzapine (5mg) is delivered orally after dinner.

DRUG

Dexamethasone+NK-1 RA+5-HT3 RA

On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.

Trial Locations (1)

Unknown

Fifth Affilliated Hospital of Sun Yat-sen University, Zhuhai

All Listed Sponsors

lead

Fifth Affiliated Hospital, Sun Yat-Sen University

OTHER

NCT04437017 - Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV | Biotech Hunter | Biotech Hunter